135 related articles for article (PubMed ID: 11550167)
1. GD2 synthase: a new molecular marker for detecting neuroblastoma.
Lo Piccolo MS; Cheung NK; Cheung IY
Cancer; 2001 Aug; 92(4):924-31. PubMed ID: 11550167
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR.
Cheung IY; Cheung NK
Clin Cancer Res; 2001 Jun; 7(6):1698-705. PubMed ID: 11410509
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma.
Cheung IY; Lo Piccolo MS; Kushner BH; Kramer K; Cheung NK
J Clin Oncol; 2003 Mar; 21(6):1087-93. PubMed ID: 12637475
[TBL] [Abstract][Full Text] [Related]
5. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
[TBL] [Abstract][Full Text] [Related]
6. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.
Cheung IY; Barber D; Cheung NK
Clin Cancer Res; 1998 Nov; 4(11):2801-5. PubMed ID: 9829745
[TBL] [Abstract][Full Text] [Related]
7. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
Cheung IY; Sahota A; Cheung NK
Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
[TBL] [Abstract][Full Text] [Related]
8. Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology.
Pagani A; Macri L; Faulkner LB; Tintori V; Paoli A; Garaventa A; Bussolati G
Diagn Mol Pathol; 2002 Jun; 11(2):98-106. PubMed ID: 12045713
[TBL] [Abstract][Full Text] [Related]
9. Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer.
Chen LC; Brown AB; Cheung IY; Cheung NK; Kris MG; Krug LM
Lung Cancer; 2010 Feb; 67(2):216-20. PubMed ID: 19457569
[TBL] [Abstract][Full Text] [Related]
10. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
[TBL] [Abstract][Full Text] [Related]
11. Sialyltransferase STX (ST8SiaII): a novel molecular marker of metastatic neuroblastoma.
Cheung IY; Vickers A; Cheung NK
Int J Cancer; 2006 Jul; 119(1):152-6. PubMed ID: 16450393
[TBL] [Abstract][Full Text] [Related]
12. Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.
Corrias MV; Parodi S; Haupt R; Lacitignola L; Negri F; Sementa AR; Dau D; Scuderi F; Carlini B; Bianchi M; Casale F; Faulkner L; Garaventa A
Br J Cancer; 2008 Jan; 98(2):263-9. PubMed ID: 18182983
[TBL] [Abstract][Full Text] [Related]
13. Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients.
Corrias MV; Haupt R; Carlini B; Parodi S; Rivabella L; Garaventa A; Pistoia V; Dallorso S
Clin Cancer Res; 2006 Oct; 12(19):5680-5. PubMed ID: 17020970
[TBL] [Abstract][Full Text] [Related]
14. Useful markers for detecting minimal residual disease in cases of neuroblastoma.
Ootsuka S; Asami S; Sasaki T; Yoshida Y; Nemoto N; Shichino H; Chin M; Mugishima H; Suzuki T
Biol Pharm Bull; 2008 Jun; 31(6):1071-4. PubMed ID: 18520032
[TBL] [Abstract][Full Text] [Related]
15. Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE.
Cheung IY; Cheung NK
Med Pediatr Oncol; 2001 Jan; 36(1):210-2. PubMed ID: 11464887
[TBL] [Abstract][Full Text] [Related]
16. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
Bozzi F; Luksch R; Collini P; Gambirasio F; Barzanò E; Polastri D; Podda M; Brando B; Fossati-Bellani F
Diagn Mol Pathol; 2004 Sep; 13(3):135-43. PubMed ID: 15322424
[TBL] [Abstract][Full Text] [Related]
17. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.
Schumacher-Kuckelkorn R; Volland R; Gradehandt A; Hero B; Simon T; Berthold F
Pediatr Blood Cancer; 2017 Jan; 64(1):46-56. PubMed ID: 27654028
[TBL] [Abstract][Full Text] [Related]
18. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
[TBL] [Abstract][Full Text] [Related]
19. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.
Cheung IY; Cheung NK
Clin Cancer Res; 1997 May; 3(5):821-6. PubMed ID: 9815755
[TBL] [Abstract][Full Text] [Related]
20. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
